Amydis Diagnostics

Amydis Diagnostics is developing a first-in-class, non-invasive diagnostic platform that uses proprietary ocular tracers to detect molecular biomarkers in the eye via routine eye exams. This technology targets major unmet needs in neurodegenerative (e.g., Alzheimer's, Parkinson's, ALS), ophthalmic, and cardiovascular diseases by enabling earlier and more accessible diagnosis. The company is advancing its pipeline through human clinical trials with support from significant NIH grants and foundation awards, positioning itself to leverage the existing, widespread infrastructure of eye care providers as a new front line for systemic disease detection.

Proprietary small-molecule fluorophore ocular tracers that selectively bind to disease-related molecular biomarkers (e.g., amyloid, alpha-synuclein) in the eye. The fluorescent signal is detected using standard ocular imaging cameras, enabling non-invasive, digital diagnosis and monitoring.

Competition includes companies using AI to analyze standard retinal images (OCT, fundus photos) for signs of neurodegeneration, as well as developers of blood-based biomarkers (e.g., Simoa, Mass Spectrometry) for diseases like Alzheimer's. Amydis's approach with targeted molecular tracers is distinct and first-in-class, but it may face future competition from other firms developing similar ocular imaging agents.